Holographic Traction Force Microscopy

Traction Force Microscopy (TFM) computes the forces exerted at the surface of an elastic material by measuring induced deformations in volume. It is used to determine the pattern of the adhesion forces exerted by cells or by cellular assemblies grown onto a soft deformable substrate. Typically, colloidal particles are dispersed in the substrate and their displacement is monitored by fluorescent microscopy. As with any other fluorescent techniques, the accuracy in measuring a particule’s position is ultimately limited by the number of evaluated fluorescent photons. Here, we present a TFM technique based on the detection of probe particle displacements by holographic tracking microscopy. We show that nanometer scale resolutions of the particle displacements can be obtained and determine the maximum volume fraction of markers in the substrate. We demonstrate the feasibility of the technique experimentally and measure the three-dimensional force fields exerted by colorectal cancer cells cultivated onto a polyacrylamide gel substrate

Monomeric Ti(IV)-based complexes incorporating luminescent nitrogen ligands: synthesis, structural characterization, emission spectroscopy and cytotoxic activities

This manuscript describes the synthesis of a series of neutral titanium(IV) monomeric complexes constructed around a TiO4N2 core. The two nitrogen atoms that compose the coordination sphere of the metallic center belong to 2,2′-bipyrimidine ligands homo-disubstituted in the 4 and 4′ positions by methyl (2a), phenylvinyl (2b), naphthylvinyl (2c) or anthrylvinyl (2d) groups. The crystal structures of these complexes named [Ti(1)2(2a)], [Ti(1)2(2b)], [Ti(1)2(2c)] and [Ti(1)2(2d)] (where 1 is a 2,2′-biphenolato ligand substituted in the 6 and 6′ positions by phenyl groups) are reported. The hydrolytic stability of the four complexes is evaluated by monitoring the evolution of the free 2a–d signals by 1H NMR spectroscopy. For the conditions tested (6 mM, DMSO-d6/D2O: 8/1), a rather good stability with t1/2 ranging from 180 to 300 min is determined for the complexes. In the presence of an acid (DCl), the hydrolysis of [Ti(1)2(2a)] is faster than without an acid. The cytotoxic activity against gastric cancer cells of the titanium-based compounds and the free disubstituted 2,2′-bipyrimidine ligands is tested, showing IC50 ranging from 6.2 ± 1.2 μM to 274 ± 56 μM. The fluorescence studies of the ligands 2a–d, and the complexes [Ti(1)2(2a–d)] reveal an important fluorescence loss of the ligands 2c and 2d upon coordination with the Ti(1)2 fragment. Frontier orbitals obtained by DFT calculations permit us to explain this fluorescence quenching.Other supports : Centre National pour la Recherche Scientifique (CNRS, France), ARC, Ligue contre le Cancer, European action COST CM1105 (C. G.

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

peer reviewed[en] BACKGROUND: Deconvoluting the heterogenous prognosis of Human Papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OSCC) is crucial for enhancing patient care, given its rapidly increasing incidence in western countries and the adverse side effects of OSCC treatments. METHODS: Transcriptomic data from HPV-positive OSCC samples were analyzed using unsupervised hierarchical clustering, and clinical relevance was evaluated using Kaplan-Meier analysis. HPV-positive OSCC cell line models were used in functional analyses and phenotypic assays to assess cell migration and invasion, response to cisplatin, and phagocytosis by macrophages in vitro. RESULTS: We found, by transcriptomic analysis of HPV-positive OSCC samples, a ΔNp63 dependent molecular signature that is associated with patient prognosis. ΔNp63 was found to act as a tumor suppressor in HPV-positive OSCC at multiple levels. It inhibits cell migration and invasion, and favors response to chemotherapy. RNA-Seq analysis uncovered an unexpected regulation of genes, such as DKK3, which are involved in immune response-signalling pathways. In agreement with these observations, we found that ΔNp63 expression levels correlate with an enhanced anti-tumor immune environment in OSCC, and ΔNp63 promotes cancer cell phagocytosis by macrophages through a DKK3/NF-κB-dependent pathway. CONCLUSION: Our findings are the first comprehensive identification of molecular mechanisms involved in the heterogeneous prognosis of HPV-positive OSCC, paving the way for much-needed biomarkers and targeted treatment

Complex Regulation of p73 Isoforms after Alteration of Amyloid Precursor Polypeptide (APP) Function and DNA Damage in Neurons

Background: Alterations of the APP pathway or DNA damage induce neuronal cell death. Results: Alterations of the APP pathway or DNA damage increase TAp73 expression and reduce Delta Np73 protein levels. Conclusion: A tight control of the expression of p73 isoforms participates in neuronal cell death. Significance: p73 isoforms may play a role in neurodegenerative diseases such as Alzheimer and in the neurotoxicity of anticancer drug therapies

p53 and p73 display common and distinct requirements for sequence specific binding to DNA

Although p53 and p73 share considerable homology in their DNA-binding domains, there have been few studies examining their relative interactions with DNA as purified proteins. Comparing p53 and p73β proteins, our data show that zinc chelation by EDTA is significantly more detrimental to the ability of p73β than of p53 to bind DNA, most likely due to the greater effect that the loss of zinc has on the conformation of the DNA-binding domain of p73. Furthermore, prebinding to DNA strongly protects p73β but not p53 from chelation by EDTA suggesting that DNA renders the core domain of p73 less accessible to its environment. Further exploring these biochemical differences, a five-base sub-sequence was identified in the p53 consensus binding site that confers a greater DNA-binding stability on p73β than on full-length p53 in vitro. Surprisingly, p53 lacking its C-terminal non-specific DNA-binding domain (p53Δ30) demonstrates the same sequence discrimination as does p73β. In vivo, both p53 and p73β exhibit higher transactivation of a reporter with a binding site containing this sub-sequence, suggesting that lower in vitro dissociation translates to higher in vivo transactivation of sub-sequence-containing sites

Caractérisation des propriétés anticancéreuses des composés dérivés du ruthénium (mode d'action, optimisation et développement d outils expérimentaux.)

Au cours des dernières années, une nouvelle classe de composés anticancéreux à base de ruthénium, appelés RDCs (Ruthenium-Derived Compounds), a été développé pour dépasser les limitations des agents chimiothérapiques contenants du platine. Contrairement à ces derniers, l activité anticancéreuse des RDCs est en partie indépendante de l'interaction avec l'ADN. L objectif principal de ma thèse a été ainsi de comprendre les mécanismes moléculaires quiinter viennent dans l action anticancéreuse et antimétastatique des RDCs au-delà du dommage à l ADN.J ai démontré que le RDC11, contrairement au cisplatine, affecte les voies de signalisation de HIF-1 et mTOR, deux voies qui jouent un rôle clé dans le métabolisme cellulaire et qui sont souvent altérées dans les cellules cancéreuses.En parallèle, j ai effectué un analyse structure/activité pour sélectionner des nouveaux RDCs ayant meilleures propriétés chimiques et pharmacologiques que le RDC11. Cette étude a permis d identifier deux nouveaux RDCs qui réduisent la croissance tumorale in vivo avec un dosage beaucoup plus faible que le RDC11 et qui induisent la mort des cellules cancéreuses par une surproduction d'espèces réactives de l'oxygène et par l'activation de la caspase8. En conclusion, mes travaux ont conduit à l identification de nouveaux mécanismes à la base de l activité anticancéreuse du RDC11 qui pourraient expliquer certaines différences entre le mode d action du RDC11 et du cisplatine. De plus, ils ont permis de sélectionner deux nouveaux RDCs plus efficaces que le RDC11. Ces résultat sont un impact important pour le développement de nouvelles thérapies anticancéreuses ou antimétastatiques.In recent years, a new class of anticancer ruthenium-based drugs, called RDCs (Ruthenium-Derived Compounds), has been developed to overcome the limitations of classic platinum chemotherapeutics. Unlike the latter, the anticancer activity of RDCs is in part independent of DNA interaction. Therefore, the main objective of my thesis work was to elucidate the molecular mechanisms involved in RDCs anticancer and antimetastatic activity beyond DNA damage. I demonstrated that RDC11, unlike cisplatin, affects the HIF-1 and mTOR signaling pathways, two pathways that play a key role in cellular metabolism and that are frequently altered in cancer cells. In parallel, I performed a structure/activity analysis to select new RDCs endowed with better chemical and pharmacological properties than RDC11. This study allowed to identify two novel RDCs that reduce tumor growth in vivo at much lower doses than RDC11 and that induce cancer cell death by an overproduction of reactive oxygen species and activation of caspase 8. In conclusion, my work led to the identification of new mechanisms underlying the anticancer activity of RDC11 that could explain some of the differences between the mode of action of RDC11 and cisplatin. In addition, it allowed to select two novel RDCs which are more effective than RDC11. These results have a significant impact on the development of new anticancer or antimetastatic therapies.STRASBOURG-Bib.electronique 063 (674829902) / SudocSudocFranceF

Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo

International audienceRef-1 is a multifunctional protein that stimulates DNA binding by a number of transcription factors and serves as the abasic (A/P) endonuclease in base excision repair. Ref-1 was discovered to be a potent activator of p53 DNA binding in vitro. To address the physiological significance of the effects of Ref-1 on p53, we have analyzed its role in regulating p53 function in vivo. We found that Ref-1 over-expression enhances the ability of p53 to transactivate a number of p53 target promoters and increases the ability of p53 to stimulate endogenous p21 and cyclin G expression. Additionally, it was observed that Ref-1 associates with p53 in vivo and in vitro. Importantly, downregulation of Ref-1 (by antisense) causes a marked reduction in p53 induction of p21 mRNA and protein, as well as diminished ability of p53 to transactivate the p21 and Bax promoters. Moreover, Ref-1 levels are correlated with the extent of apoptosis induced by p53. Finally, we observed that Ref-1 cooperates with a DNA-damaging compound, camptothecin, to stimulate the transcriptional activity of p53. Together these data indicate that Ref-1 is a key cellular regulator of p53

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?

Gastric cancer (GC) is one of the most aggressive cancers. Therapeutic treatments are based on surgery combined with chemotherapy using a combination of platinum-based agents. However, at metastatic stages of the disease, survival is extremely low due to late diagnosis and resistance mechanisms to chemotherapies. The development of new classifications has not yet identified new prognostic markers for clinical use. The studies of epigenetic processes highlighted the implication of histone acetylation status, regulated by histone acetyltransferases (HATs) and by histone deacetylases (HDACs), in cancer development. In this way, inhibitors of HDACs (HDACis) have been developed and some of them have already been clinically approved to treat T-cell lymphoma and multiple myeloma. In this review, we summarize the regulations and functions of eighteen HDACs in GC, describing their known targets, involved cellular processes, associated clinicopathological features, and impact on survival of patients. Additionally, we resume the in vitro, pre-clinical, and clinical trials of four HDACis approved by Food and Drug Administration (FDA) in cancers in the context of GC

Current Clinical and Pre-Clinical Imaging Approaches to Study the Cancer-Associated Immune System

International audienceIn the light of the success and the expected growth of its arsenal, immuno-therapy may become the standard neoadjuvant procedure for many cancers in the near future. However, aspects such as the identity, organization and the activation status of the peri- and intra-tumoral immune cells would represent important elements to weigh in the decision for the appropriate treatment. While important progress in non-invasive imaging of immune cells has been made over the last decades, it falls yet short of entering the clinics, let alone becoming a standard procedure. Here, we provide an overview of the different intra-vital imaging approaches in the clinics and in pre-clinical settings and discuss their benefits and drawbacks for assessing the activity of the immune system, globally and on a cellular level. Stimulated by further research, the future is likely to see many technological advances both on signal detection and emission as well as image specificity and resolution to tackle current hurdles. We anticipate that the ability to precisely determine an immune stage of cancer will capture the attention of the oncologist and will create a change in paradigm for cancer therapy

p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells

The p53 tumor suppressor protein, found mutated in over 50% of all human tumors, is a sequence-specific transcriptional activator. Recent studies have identified a p53 relative, termed p73. We were interested in determining the relative abilities of wild-type and mutant forms of p53 and p73α and -β isoforms to transactivate various p53-responsive promoters. We show that both p73α and p73β activate the transcription of reporters containing a number of p53-responsive promoters in the p53-null cell line H1299. However, a number of significant differences were observed between p53 and p73 and even between p73α and p73β. Additionally, a Saccharomyces cerevisiae-based reporter assay revealed a broad array of transcriptional transactivation abilities by both p73 isoforms at 37°C. Recent data have shown that p73 can associate with p53 by the yeast two-hybrid assay. When we examined complex formation in transfected mammalian cells, we found that p73α coprecipitates with mutant but not wild-type p53. Since many tumor-derived p53 mutants are capable of inhibiting transactivation by wild-type p53, we tested the effects of two representative hot-spot mutants (R175H and R248W) on p73. By cotransfecting p73α along with either p53 mutant and a p53-responsive reporter, we found that both R175H and R248W reduces the transcriptional activity of p73α. This decrease in transcriptional activity is correlated with the reduced ability of p73α to promote apoptosis in the presence of tumor-derived p53 mutants. Our data suggest the possibility that in some tumor cells, an outcome of the expression of mutant p53 protein may be to interfere with the endogenous p73 protein